Latest Breaking News On - Tiziana life - Page 6 : comparemela.com

Phase 1 Results Are Extraordinary, Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment - Bayer (OTC:BAYRY), Sanofi (NASDAQ:SNY)

Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in microglia activity,

Gabriele cerroneHowardl weinerDrug administrationTiziana lifePositron emission tomographyExpanded accessSecondary progressive multiple sclerosisScientific advisory boardPrepares for phaseMatteo vistocco

Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA) - Tiziana Life Sciences (NASDAQ:TLSA), Sanofi (NASDAQ:SNY)

Tiziana Life Sciences (NASDAQ: TLSA) is a biotechnology company establishing itself in a cutting-edge position in the market with its b

Provention bioTea programProceedings of the national academy sciencesDrug administrationTiziana lifeSecondary progressive multiple sclerosisApplications for foralumabNational academyInvestigational new drugHans reniers

Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short Interest

Tiziana Life Sciences Ltd (NASDAQ:TLSA – Free Report) was the recipient of a significant growth in short interest in June. As of June 15th, there was short interest totalling 207,400 shares, a growth of 139.2% from the May 31st total of 86,700 shares. Based on an average trading volume of 211,100 shares, the days-to-cover ratio […]

Cantor fitzgeraldTiziana life sciencesJpmorgan chase coTiziana life sciences price performanceInstitutional trading of tiziana life sciencesTiziana life sciences ltdNews ratings for tiziana life sciences dailyFree reportTiziana lifeStreet corpLife sciencesLife sciences ltdTiziana life sciences daily

Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise

Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomPaul spencerProvention bioBusiness developmentTiziana life sciences ltdProceedings of the national academy sciencesTiziana life sciencesMultiple sclerosisLife sciences ltdLondon based tiziana life sciencesNational academyResults announced with further trials plannedTiziana life

Treatments For Non-Active Secondary Progressive Multiple Sclerosis

Treatments For Non-Active Secondary Progressive Multiple Sclerosis .

City ofUnited kingdomPaul spencerProvention bioTiziana life sciencesTiziana life sciences ltdProceedings of the national academy sciencesNews networkBusiness developmentMultiple sclerosisLondon based tiziana life sciencesTreatment theNational academyResults announced with further trials plannedTiziana lifeInvestor relations